Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
TC Biopharm (Holdings) Plc Sponsored ADR ( (TCBP) ) has shared an update.
On February 5, 2025, TC BioPharm announced a change in its American Depositary Shares (ADS) ratio from one ADS representing 200 ordinary shares to one ADS representing 4,000 ordinary shares, effective February 10, 2025. This ADS Ratio Change effectively acts as a one-for-20 reverse ADS split, expected to proportionally increase the ADS trading price. The underlying ordinary shares remain unaffected, and the company’s public warrants have been adjusted accordingly, ensuring the exercise price remains unchanged.
More about TC Biopharm (Holdings) Plc Sponsored ADR
TC BioPharm is a clinical-stage biopharmaceutical company focused on developing and commercializing gamma-delta T-cell therapies for cancer treatment. The company is a leader in this field, conducting pivotal clinical studies and trials, particularly in acute myeloid leukemia using its proprietary allogeneic CryoTC technology.
YTD Price Performance: -61.05%
Average Trading Volume: 2,053,701
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $99.64K
For a thorough assessment of TCBP stock, go to TipRanks’ Stock Analysis page.
